PEA and SEA Blend for Anti-Inflammatory Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid derivatives, despite promising experimental evidence, have limited clinical applications due to their interaction with central CB1 receptors, leading to unwanted effects, and there is a need for compounds with specific agonist activities for peripheral CB2 receptors that do not interact with central receptors.
Innovation Solution
The combination of palmitoyl ethanolamide (PEA) and stearoyl ethanolamide (SEA) derivatives exhibits synergistic anti-inflammatory effects in vitro, providing a cannabimimetic pharmacological activity superior to single components, potentially targeting different receptor systems to minimize central effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoid derivatives are used to treat inflammatory pathologies, then anti-inflammatory effects are achieved, but unwanted central effects occur due to interaction with CB1 receptors
Solution Approach 1:
The patent segments the cannabinoid molecule into two distinct components: PEA (palmitoyl ethanolamide) and SEA (stearoyl ethanolamide). This segmentation allows each component to target specific receptor systems - PEA primarily activates CB2 receptors for anti-inflammatory effects, while SEA acts as a negative allosteric modulator to reduce CB1 receptor activation and minimize central unwanted effects.
Solution Approach 2:
SEA functions as an intermediary substance that modulates the interaction between cannabinoids and CB1 receptors. By acting as a negative allosteric modulator, SEA interferes with the binding and activation of CB1 receptors, thereby preventing the transmission of unwanted central signals while allowing PEA to exert its anti-inflammatory effects through CB2 receptors.
2Reliability
If single cannabinoid derivatives are used, then specific pharmacological activity is achieved, but the pharmacological activity is insufficient compared to combination therapy
Solution Approach 1:
The patent merges two distinct cannabinoid derivatives (PEA and SEA) into a single pharmaceutical composition. This combination leverages the complementary mechanisms of action: PEA provides direct CB2 receptor agonist activity for anti-inflammatory effects, while SEA provides negative allosteric modulation of CB1 receptors. The synergistic interaction between these two components produces enhanced therapeutic effectiveness that exceeds the sum of their individual effects.
Solution Approach 2:
The pharmaceutical composition represents a composite material system where PEA and SEA work together in a coordinated manner. The composite nature of this formulation allows for simultaneous engagement of multiple receptor systems (CB2 activation and CB1 modulation), creating a more sophisticated and effective therapeutic agent than either component could achieve alone.
Data Source
AI summary
The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can be in patches, suppositories, ovules, pessaries, aerosol or spray, emulsions, suspensions, solutions. Said pharmaceutical formulations are useful for the treatment or prevention of skin pathologies, for the treatment or prevention of gynaecological pathologies, for the treatment of disorders or pathologies characterised by improper metabolism of fatty acids as well as for the treatment of disorders or pathologies characterised by inflammatory states.